Childhood-onset Eosinophilic Granulomatosis with Polyangiitis (formerly Churg-Strauss Syndrome): A Contemporary Single-center Cohort

被引:46
|
作者
Gendelman, Samantha [1 ]
Zeft, Andrew [2 ,3 ]
Spalding, Steven J. [2 ,3 ]
机构
[1] Cleveland Clin, Dept Allergy & Immunol, Resp Inst, Cleveland, OH 44195 USA
[2] Cleveland Clin, Orthoped & Rheumatol Inst, Ctr Vasculitis Care & Res, Cleveland, OH 44195 USA
[3] Cleveland Clin, Ctr Pediat Rheumatol, Inst Pediat, Cleveland, OH 44195 USA
关键词
EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS; COHORT STUDY; CHURG-STRAUSS SYNDROME; PEDIATRIC VASCULITIS; ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; SYSTEMIC VASCULITIS; PREVALENCE;
D O I
10.3899/jrheum.120808
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To date only 38 cases of childhood-onset eosinophilic granulomatosis with polyangiitis (cEGPA; formerly Churg-Strauss syndrome) have been reported. Additional patients with cEGPA could enhance the understanding of this rare and life-threatening condition. Our objectives were (1) to determine the frequency of specific organ system involvement; (2) to examine initial therapeutic regimen; and (3) to document disease and therapy-related morbidity in a contemporary cohort of patients with cEGPA. Methods. Retrospective review of patients evaluated at the Cleveland Clinic between 2003 and 2011 who met either American College of Rheumatology or Lanham criteria for EGPA and whose age was < 1 8 years at symptom onset. Results. Nine patients (8 female; 7 white) were identified. Median age at onset of rhinitis/asthma symptom was 13 years and median age at diagnosis of cEGPA was 15 years. All patients demonstrated eosinophilia, upper airway disease (allergic rhinitis, chronic sinusitis, and/or nasal polyps), and pulmonary involvement. Other frequently involved organ systems included musculoskeletal (67%), gastrointestinal (67%), cutaneous (67%), neurologic (56%), and cardiac (44%). Antineutrophil cytoplasmic antibody (ANCA) serologies were negative in all patients. The medications used most frequently for initial therapy included oral (44%) or intravenous corticosteroids (56%) and azathioprine (67%). Disease or therapeutic complications occurred in half of the cohort and included heart failure, stroke, and sequela from longterm, high-dose steroids. Conclusion. Eosinophilia, in combination with upper airway, pulmonary, musculoskeletal, neurologic, and cardiac manifestations, is frequently observed in cEGPA. ANCA titers are often negative. Steroids are the mainstay of initial therapy but steroid-related side effects occur regularly.
引用
收藏
页码:929 / 935
页数:7
相关论文
共 50 条
  • [31] Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
    David Aguirre-Valencia
    Iván Posso-Osorio
    Juan-Carlos Bravo
    Fabio Bonilla-Abadía
    Gabriel J. Tobón
    Carlos A. Cañas
    Clinical Rheumatology, 2017, 36 : 2159 - 2162
  • [32] Eosinophilic granulomatosis with polyangiitis (churg-strauss syndrome) without respiratory symptoms in a boy
    Selçuk Yüksel
    Havva Evrengül
    Tülay Becerir
    Ali Koçyiğit
    Mine Cinbiş
    Neşe Çallı Demirkan
    Pediatric Rheumatology, 12 (Suppl 1)
  • [33] Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
    Jens Thiel
    Fabian Hässler
    Ulrich Salzer
    Reinhard E Voll
    Nils Venhoff
    Arthritis Research & Therapy, 15
  • [34] Ophthalmic Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss Syndrome): A Systematic Review of the Literature
    Akella, Sruti S.
    Schlachter, Dianne M.
    Black, Evan H.
    Barmettler, Anne
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2019, 35 (01): : 7 - 16
  • [35] Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss) Relapsing as Bullous Eruption
    Sherman, Shany
    Gal, Noa
    Didkovsky, Elena
    Molad, Yair
    Pavlovsky, Lev
    Hodak, Emmilia
    ACTA DERMATO-VENEREOLOGICA, 2017, 97 (03) : 406 - 407
  • [36] Pharmacological approach to treating eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
    Groh, Matthieu
    Dunogue, Bertrand
    Guillevin, Loic
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (05): : 505 - 515
  • [37] A multicenter survey of rituximab for eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
    Hot, A.
    Guerry, M. J.
    Smith, R.
    Sivasothy, P.
    Guillevin, L.
    Merkel, P.
    Jayne, D.
    PRESSE MEDICALE, 2013, 42 (04): : 698 - 698
  • [38] THE CHURG-STRAUSS ARREST: CARDIAC INVOLVEMENT IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
    Gadela, Naga Vaishnavi
    Henry, Lucie
    Putra, Ilham
    Jaiswal, Abhishek
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 2245 - 2245
  • [39] NEW THERAPEUTIC APPROACHES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS)
    Guillevin, Loic
    Terrier, Benjamin
    RHEUMATOLOGY, 2017, 56 : 15 - 16
  • [40] Mepolizumab For Refractory Asthma In Eosinophilic Granulomatosis With Polyangiitis (churg-Strauss)
    Saygin, D.
    Arunachalam, A.
    Boyle, M.
    McCarroll, S.
    Micklewright, S.
    Erzurum, S. C.
    Highland, K.
    Khatri, S. B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195